Edition:
United Kingdom

People: China Regenerative Medicine International Ltd (8158.HK)

8158.HK on Hong Kong Stock

0.16HKD
6:00am BST
Change (% chg)

HK$-0.01 (-5.29%)
Prev Close
HK$0.17
Open
HK$0.16
Day's High
HK$0.16
Day's Low
HK$0.16
Volume
5,000
Avg. Vol
683,234
52-wk High
HK$3.60
52-wk Low
HK$0.14

Sun, Xiaohu 

Dr. Sun Xiaohu is Chief Operating Officer of the Company. He is a doctor of medicine (immunology) from Shanghai Jiao Tong University School of Medicine and holds an EMBA degree from Shanghai Jiao Tong University. Dr. Sun has 36 years’ experience in listed biotechnology companies, pharmaceutical companies, medical enterprises, research institutes and hospitals; and 18 years’ experience as chief executive officers and senior executives in domestic and international pharmaceutical and medical device companies. He is a senior professional manager with good medical education background. Dr. Sun was the operation director and marketing director of VCANBIO; the general manager of Shanghai Claison Bio-tech Co., Ltd; the general manager of Shanghai Donghai Pharmaceutical Co., Ltd and its three branches; the marketing director of Heho Biotech (Shanghai) Co., Ltd.* under Morningside Group; the assistant group general manager of Vitop Bioenergy (China) Limited general manager of its Shanghai company; the director of East China office of Tat Lung Medical Treatment Technology Limited, Hong Kong; the vice president of marketing of Shenzhen Biological Valley Technology Investment Co., Ltd; and the administrative physician/assistant to department director of Qingdao University Medical College.

Basic Compensation

Total Annual Compensation, --
Restricted Stock Award, --
Long-Term Incentive Plans, --
All Other, --
Fiscal Year Total, --

Options Compensation

  Quantity Market Value
Exercisable -- --
Unexercisable -- --
Exercised -- --